Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Pharma Astellas Licenses MorphoSys' HuCAL Library

NEW YORK (GenomeWeb News) — Astellas Pharma will use MorphoSys’ HuCAL Gold antibody library in its drug-discovery efforts, MorphoSys said today.
 
Under the agreement, MorphoSys will receive an up-front payment and user fees over the course of the license, which may last up to five years.
 
MorphoSys said it could also receive research funding from preclinical and clinical development of compounds, as well as licensing, milestone, and royalty payments. 
 
Astellas will use the HuCAL library at its facilities in Tsukuba, Japan, and has the option to start antibody projects over the span of the agreement, MorphoSys said.
 
The companies added a collaborative option into the agreement, under which MorphoSys would “generate novel HuCAL antibodies against targets provided by Astellas,” MorphoSys said.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.